Larché M - Search Results

1

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.

Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoef A, Maillère B, Kay AB, Larché M. Worm M, et al. Among authors: larche m. J Allergy Clin Immunol. 2011 Jan;127(1):89-97, 97.e1-14. doi: 10.1016/j.jaci.2010.11.029. J Allergy Clin Immunol. 2011. PMID: 21211644 Clinical Trial.

2

The potential of peptide immunotherapy in allergy and asthma.

Ali FR, Kay AB, Larché M. Ali FR, et al. Among authors: larche m. Curr Allergy Asthma Rep. 2002 Mar;2(2):151-8. doi: 10.1007/s11882-002-0010-5. Curr Allergy Asthma Rep. 2002. PMID: 11892095 Review.

3

Peptide-based vaccines in the treatment of specific allergy.

Alexander C, Kay AB, Larché M. Alexander C, et al. Among authors: larche m. Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):353-61. doi: 10.2174/1568010023344562. Curr Drug Targets Inflamm Allergy. 2002. PMID: 14561182 Review.

4

Allergen immunotherapy with cat allergen peptides.

Kay AB, Larché M. Kay AB, et al. Among authors: larche m. Springer Semin Immunopathol. 2004 Feb;25(3-4):391-9. doi: 10.1007/s00281-003-0146-y. Epub 2003 Sep 30. Springer Semin Immunopathol. 2004. PMID: 15007637 Review.

5

T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.

Verhoef A, Alexander C, Kay AB, Larché M. Verhoef A, et al. Among authors: larche m. PLoS Med. 2005 Mar;2(3):e78. doi: 10.1371/journal.pmed.0020078. Epub 2005 Mar 29. PLoS Med. 2005. PMID: 15783262 Free PMC article. Clinical Trial.

6

Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, Hafner RP. Patel D, et al. Among authors: larche m. J Allergy Clin Immunol. 2013 Jan;131(1):103-9.e1-7. doi: 10.1016/j.jaci.2012.07.028. Epub 2012 Sep 13. J Allergy Clin Immunol. 2013. PMID: 22981787 Free article. Clinical Trial.

7

One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence.

Pfaar O, Bousquet J, Durham SR, Kleine-Tebbe J, Larché M, Roberts G, Shamji MH, Gerth van Wijk R. Pfaar O, et al. Among authors: larche m. Allergy. 2022 Feb;77(2):454-468. doi: 10.1111/all.15023. Epub 2021 Sep 27. Allergy. 2022. PMID: 34315190 Review.

8

Peptide-mediated immune responses in specific immunotherapy.

Haselden BM, Kay AB, Larché M. Haselden BM, et al. Among authors: larche m. Int Arch Allergy Immunol. 2000 Aug;122(4):229-37. doi: 10.1159/000024403. Int Arch Allergy Immunol. 2000. PMID: 10971112 Review.

9

Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study.

Smith TR, Alexander C, Kay AB, Larché M, Robinson DS. Smith TR, et al. Among authors: larche m. Allergy. 2004 Oct;59(10):1097-101. doi: 10.1111/j.1398-9995.2004.00601.x. Allergy. 2004. PMID: 15355469 Clinical Trial.

10

The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.

Alexander C, Tarzi M, Larché M, Kay AB. Alexander C, et al. Among authors: larche m. Allergy. 2005 Oct;60(10):1269-74. doi: 10.1111/j.1398-9995.2005.00885.x. Allergy. 2005. PMID: 16134993 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters